SC 13D/A 1 ea141461-13da8meyer_aurismed.htm AMENDMENT NO. 8 TO SCHEDULE 13D

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

(Amendment No. 8)

Under the Securities Exchange Act of 1934

Auris Medical Holding Ltd.

(Name of Issuer)

Common Stock, par value CHF 0.01 per share

(Title of Class of Securities)

G07025102

(CUSIP Number)

Thomas Meyer

Clarendon House, 2 Church Street

Hamilton HM 11, Bermuda

+41 (0) 41 729 71 94

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

May 21, 2021

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. G07025201

1.	Names of Reporting Persons. I.R.S. Identification Nos. of Above Persons (Entities Only): Thomas Meyer
2.	Check the Appropriate Box if a Member of a Group (See Instructions): (a) ☐ (b) ☐
3.	SEC Use Only

4.	Source of Funds (See Instructions): PF
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e): ☐
6.	Citizenship or Place of Organization: Switzerland

Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power: 817,263*
	8.	Shared Voting Power: 0
	9.	Sole Dispositive Power: 817,263*
	10.	Shared Dispositive Power: 0

11.	Aggregate Amount Beneficially Owned by Each Reporting Person: 817,263*
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): ☐
13.	Percent of Class Represented by Amount in Row (11): 6.3%*
14.	Type of Reporting Person (See Instructions): IN

*The foregoing beneficial ownership percentage is based upon 12,869,587 common shares, par value CHF 0.01 per share (the “Common Shares”) of Auris Medical Holding Ltd., a Bermuda corporation (the “Issuer”), issued and outstanding as of May 21, 2021, based on information from the Issuer. Reporting Person beneficially owns 817,263 Common Shares consisting of 700,000 Common Shares and warrants and options to purchase up to 117,263 Common Shares exercisable within 60 days of the date hereof.

Explanatory Note

This Amendment No. 8 (the “Amendment”) amends and supplements the Schedule 13D filed by the Reporting Person (as defined in the Schedule 13D) with the Securities and Exchange Commission (the “SEC”) on April 3, 2018, as amended on July 23, 2018 as further amended on November 21, 2018, as further amended on June 13, 2018, and as further amended on August 12, 2019, as further amended on August 20, 2020 as further amended on October 6, 2020, as further amended on December 4, 2020 (the “Schedule 13D”). Except as specifically provided herein, this Amendment does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D.

Item 3.

Source and Amount of Funds or Other Consideration

Item 3 of the Schedule 13D is hereby supplemented by adding the following:

On December 31, 2020, the Reporting Person purchased 25,969 Common Shares at a purchase price of $2.6235 per share for a total of $68,128.41. Reporting Person purchased these Common Shares with personal funds.

On January 6, 2021, the Reporting Person purchased 5,000 Common Shares at a purchase price of $2.55 per share for a total of $12,750.00. Reporting Person purchased these Common Shares with personal funds.

On January 20, 2021, in lieu of a cash bonus, the Reporting Person received 38,179 common shares, par value CHF 0.01 per share (the “Common Shares”). Such share issuance was approved by the compensation committee of the Issuer.

On April 14, 2021, the Reporting Person purchased 10,000 Common Shares at a purchase price of $3.8080 per share for a total of $38,080.00. Reporting Person purchased these Common Shares with personal funds.

On April 15, 2021, the Reporting Person purchased 10,000 Common Shares at a purchase price of $3.64 per share for a total of $36,400.00. Reporting Person purchased these Common Shares with personal funds.

On April 16, 2021, the Reporting Person purchased 20,000 Common Shares at a purchase price of $3.3925 per share for a total of $67,850.00. Reporting Person purchased these Common Shares with personal funds.

On April 22, 2021, the Reporting Person purchased 5,000 Common Shares at a purchase price of $2.96 per share for a total of $14,800.00. Reporting Person purchased these Common Shares with personal funds.

On May 5, 2021, the Reporting Person purchased 11,821 Common Shares at a purchase price of $2.925 per share for a total of $34,576.43. Reporting Person purchased these Common Shares with personal funds.

On May 6, 2021, the Reporting Person purchased 5,000 Common Shares at a purchase price of $2.86 per share for a total of $14,300.00. Reporting Person purchased these Common Shares with personal funds.

The Reporting Person has not borrowed any funds to effectuate the transactions whereby he received the securities that are the subject of this filing on Schedule 13D.

Item 5.

Interest in Securities of the Issuer

Item 5 of the Schedule 13D is hereby amended by deleting it in its entirety and substituting the following in lieu thereof:

(a)

The information contained on the cover pages to this Schedule 13D/A is hereby incorporated herein by reference. As of the Filing Date there are 12,869,587 Common Shares outstanding. The Reporting Person beneficially owns 817,263 Common Shares including Common Shares that the Reporting Person has the right to acquire within 60 days of the Filing Date upon exercise of outstanding options and warrants.

(b)

The Reporting Person holds sole power to vote and dispose over all of the Common Shares of the Issuer that he beneficially owns.

(c)

The information provided in Item 3 and Item 4 is incorporated by reference herein.

(d)

Not applicable.

(e)

Not applicable.

Except as described herein, during the past sixty (60) days on or prior to May 21, 2021 (the “Event Date”), and from the Event Date to the Filing Date, there were no other purchases or sales of Common Shares, or securities convertible into or exchangeable for Common Shares, by the Reporting Persons or any person or entity for which the Reporting Persons possess voting or dispositive control over the securities thereof.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 21, 2021

	/s/ Thomas Meyer
	Thomas Meyer

Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001).

SEC Form SC 13D/A filed by Auris Medical Holding Ltd. (Amendment)